The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S20-S24 , September 2007

Assessing and Treating Patients With Increasing Prostate Specific Antigen Following Radical Prostatectomy

  • Howard M. Sandler

      Affiliations

    • Departments of Radiation Oncology and Urology, University of Michigan, Ann Arbor, Michigan
    • Corresponding Author InformationCorrespondence: Departments of Radiation Oncology and Urology, University of Michigan, 1500 East Medical Center Dr., Ann Arbor, Michigan 48109-0010 (telephone: 734-936-9338; FAX: 734-763-7371).
    • Financial interest and/or other relationship with Radiation Therapy Oncology Group and TAP.
    • ,
  • Mario A. Eisenberger

      Affiliations

    • Departments of Oncology and Urology, Johns Hopkins University, Baltimore, Maryland
    • Financial interest and/or other relationship with Sanofi-Aventis.

References 

  1. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134
  2. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan Z, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;17:715
  3. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000;164:101
  4. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol. 2001;165:1146
  5. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973
  6. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006;12:4018
  7. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607
  8. Cher ML, Bianco FJ, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:1387
  9. Proano JM, Sodee DB, Resnick MI, Einstein DB. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J Urol. 2006;175:1668
  10. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43:649
  11. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, The BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325
  12. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591
  13. Eisenberger MA, Partin AW, Pound C, Roostelaar CV, Epstein J, Walsh P. Natural history of progression in patients with biochemical (PSA) relapse following radical prostatectomy: update. Proc Am Soc Clin Oncol. 2003;22:Abstract 1527
  14. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433
  15. D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376
  16. Mehta SS, Lubeck DP, Sadetsky N, Pasta DJ, Carroll PR. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol. 2004;171:215
  17. Stephenson AJ, Pollack A, Kattan MW, Scardino PT. Post-prostatectomy Radiotherapy Consortium. Proc Am Soc Clin Oncol. 2006;24:Abstract 4514
  18. Feng M, Hanlon AL, Pisansky TM, Kuban DA, Catton C, Michalski JM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:S127
  19. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285
  20. Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, et al. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006;66:647
  21. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, George DJ, Partin AW. Public health impact of PSA doubling time after radical prostatectomy on prostate cancer specific and overall survival. Proc Am Soc Clin Oncol. 2006;24:Abstract 4568

PII: S0022-5347(07)01093-2

doi: 10.1016/j.juro.2007.04.034

The Journal of Urology
Volume 178, Issue 3, Supplement , Pages S20-S24 , September 2007

Article Tools

* Image Usage & Resolution